Ivosidenib (Tibsovo<sup>®</sup>) is a small molecule, orally available inhibitor of mutated cytosolic isocitrate dehydrogenase 1 (IDH1) that is being developed by Agios Pharmaceuticals for the treatment of cancer in patients with IDH1 mutations. The mutated form of the IDH1 enzyme produces a metabol...
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!